Canadian Cancer Trials Group Bulletins

Trial Management Group

Permanent Trial Closure

Four Intergroup-led trials that included Canadian Cancer Trials Group participation have recently been permanently closed:

Canadian Cancer Trials Group OV.13 (EORTC 55971) - An International Multi-Centre Randomized Phase III Study Comparing Upfront Debulking Surgery versus Neo-Adjuvant Chemotherapy in Patients with Stage IIIC or IV Epithelial Ovarian Carcinoma


Canadian Cancer Trials Group OV.19 (MRC ICON 7) - A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin And Paclitaxel) in Patients with Epithelial Ovarian Cancer


Canadian Cancer Trials Group PRC.2 (CALGB 90203) - A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone


Canadian Cancer Trials Group AL.4 (DFCI 10-175) - A Multi-Center Phase II Study in Adults with Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol

Please note that these trials no longer require action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. Any documentation submitted to Canadian Cancer Trials Group for these trials will not be accepted and will be returned to sites.

Centres should notify their REB of any outstanding ethics documents and of the final completion of this trial. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

For complete information, please visit the "Permanent Trial Closure" area of the members area here: As well, notification is posted on each trial page.